# Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Source: https://onco.cc/trials/nct05804370/  
OnCo record `nct05804370` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 5-Aminolevulinic acid in ovarian cancer, run by NX Development Corp, now recruiting.

## Summary

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) is a phase 3 interventional study registered as NCT05804370 by NX Development Corp, with 170 participants planned, started 2024-05-30 and due to reach its primary completion in 2028-09. Interventions recorded: Gleolan. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05804370
- Phase: 3
- Setting: A Phase 3 Multicenter Study of Gleolan® (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer
- Sponsor: NX Development Corp
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT05804370: https://clinicaltrials.gov/study/NCT05804370

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [5-Aminolevulinic acid (oral, for glioma surgery)](https://onco.cc/drugs/aminolevulinic-acid-gleolan/)

---
JSON: https://onco.cc/api/v1/entities/nct05804370.json